免疫检查点抑制剂治疗非小细胞肺癌的研究进展

摘要
图/表
参考文献(30)
相关文章 (15)

全文: PDF (585 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌是全球发病率和死亡率均位居前列的恶性肿瘤。目前对于肺癌的治疗仍然是一个挑战。免疫治疗时代的开启，给肺癌患者带来了新希望。当前对于免疫治疗的研究日新月异。本文概述了现阶段临床中免疫治疗的现状，包括免疫疗法的有效性和安全性。同时预测反应的生物标志物的发现，也将进一步提高免疫治疗的精准性，期望为以后优化临床免疫治疗策略提供思路和线索。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	花蕾王榕林苏海川

关键词 ：非小细胞肺癌, 免疫检查点抑制剂, 临床研究, 联合治疗, 生物标志物

Abstract：Lung cancer is one of the most malignant tumor with the highest morbidity and mortality in the world. Currently, it remains to be a challenge to cure the lung cancer. With the advent of immunotherapy, it has brought new hope to lung cancer patients. At present, the research of immunotherapy is developing and advancing rapidly. This article focuses on the present situation of clinical immunotherapy, including the effectiveness and safety. Meanwhile, this article reviews the biomarkers which predict immunotherapy response, and their emergence will further improve the accuracy of immunotherapy. It is expected to provide ideas and clues for optimizing clinical immunotherapy strategies in the future.

Key words： Non-small cell lung cancer Immune checkpoint inhibitors Clinical studies Combination therapy Biomarkers

基金资助:国家自然科学基金资助项目（81372255、819025 23）；
吴阶平医学基金资助项目（320.6750.2020-12-53）。

通讯作者: 苏海川（1970.11-），男，博士，主任医师，主要从事肿瘤早期诊断及发生机制研究。

作者简介: 花蕾（1991.10-），男，空军军医大学2018级药学专业在读硕士研究生，主要从事肿瘤早期诊断及免疫治疗研究。

引用本文:

花蕾王榕林苏海川. 免疫检查点抑制剂治疗非小细胞肺癌的研究进展[J]. 中国医药导报, 2022, 19(5): 32-35,51.
HUA Lei WANG Ronglin SU Haichuan. Research progress of immune checkpoint inhibitors in the treatment of non-small cell lung cancer#br#. 中国医药导报, 2022, 19(5): 32-35,51.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I5/32

[1] Sung H，Ferlay J，Siegel R L，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Duma N，Santana-Davila R，Molina JR. Non-Small Cell Lung Cancer：Epidemiology，Screening，Diagnosis，and Treatment [J]. Mayo Clin Proc，2019，94（8）：1623-1640.
[3] Wculek SK，Cueto FJ，Mujal AM，et al. Dendritic cells in cancer immunology and immunotherapy [J]. Nat Rev Immunol，2020，20（1）：7-24.
[4] Groth C，Hu X，Weber R，et al. Immunosuppression mediated by myeloid-derived suppressor cells （MDSCs） during tumour progression [J]. Br J Cancer，2019，120（1）：16-25.
[5] Zhang MJ，Zhang ML，Yang MY，et al. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8（+） T Cells [J]. Int J Radiat Oncol Biol Phys，2021，109（5）：1533-1546.
[6] Sumitomo R，Hirai T，Fujita M，et al. M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer [J]. Exp Ther Med，2019，18（6）：4490-4498.
[7] Kalbasi A，Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade [J]. Nat Rev Immunol，2020，20（1）：25-39.
[8] Okazaki T，Maeda A，Nishimura H，et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine [J]. Proc Natl Acad Sci U S A，2001，98（24）：13866-13871.
[9] Hosseini A，Gharibi T，Marofi F，et al. CTLA-4：From mechanism to autoimmune therapy [J]. Int Immunopharmacol，2020，80：106221.
[10] Wing K，Onishi Y，Prieto-Martin P，et al. CTLA-4 control over Foxp3+ regulatory T cell function [J]. Science，2008，322（5899）：271-275.
[11] Reck M，Rodriguez-Abreu D，Robinson AG，et al. Updated Analysis of KEYNOTE-024：Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater [J]. J Clin Oncol，2019，37（7）：537-546.
[12] Wu YL，Lu S，Cheng Y，et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC：CheckMate 078 Randomized Phase Ⅲ Clinical Trial [J]. J Thorac Oncol，2019，14（5）：867-875.
[13] Herbst RS，Giaccone G，de Marinis F，et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J]. N Engl J Med，2020，383（14）：1328-1339.
[14] Peng J，Hamanishi J，Matsumura N，et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-kappa B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer [J]. Cancer Res，2015，75（23）：5034-5045.
[15] Paz-Ares L，Vicente D，Tafreshi A，et al. A Randomized，Placebo-Controlled Trial of Pembrolizumab Plus Chem-otherapy in Patients With Metastatic Squamous NSCLC：Protocol-Specified Final Analysis of KEYNOTE-407 [J]. J Thorac Oncol，2020，15（10）：1657-1669.
[16] West H，McCleod M，Hussein M，et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chem-otherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer （IMpower130）：a multicentre，randomised，open-label，phase 3 trial [J]. Lancet Oncol，2019，20（7）：924-937.
[17] Lugade AA，Moran JP，Gerber SA，et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor [J]. J Immunol，2005，174（12）：7516-7523.
[18] Yoneda K，Kuwata T，Kanayama M，et al. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer [J]. Br J Cancer，2019，121（6）：490-496.
[19] Shaverdian N，Lisberg AE，Bornazyan K，et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer：a secondary analysis of the KEYNOTE-001 phase 1 trial [J]. Lancet Oncol，2017，18（7）：895-903.
[20] Theelen W，Chen D，Verma V，et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer：a pooled analysis of two randomised trials [J]. Lancet Respir Med，2021，9（5）：467-475.
[21] Gray JE，Villegas A，Daniel D，et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage Ⅲ NSCLC-Update from PACIFIC [J]. J Thorac Oncol，2020，15（2）：288-293.
[22] Pollack BP，Sapkota B，Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class Ⅰ and Ⅱ genes [J]. Clin Cancer Res，2011，17（13）：4400-4413.
[23] Herbst RS，Arkenau HT，Santana-Davila R，et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer，gastro-oesophageal cancer，or urothelial carcinomas （JVDF）：a multicohort，non-randomised，open-label，phase 1a/b trial [J]. Lancet Oncol，2019，20（8）：1109-1123.
[24] Creelan BC，Yeh TC，Kim SW，et al. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer [J]. Br J Cancer，2021，124（2）：383-390.
[25] Hellmann MD，Paz-Ares L，Bernabe CR，et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J]. N Engl J Med，2019，381（21）：2020-2031.
[26] Ott PA，Hu-Lieskovan S，Chmielowski B，et al. A Phase Ⅰb Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma，Non-small Cell Lung Cancer，or Bladder Cancer [J]. Cell，2020，183（2）：347-362.
[27] Topalian SL，Hodi FS，Brahmer JR，et al. Safety，activity，and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med，2012，366（26）：2443-2454.
[28] Ready N，Hellmann MD，Awad MM，et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer （CheckMate 568）：Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers [J]. J Clin Oncol，2019，37（12）：992-1000.
[29] Ramos-Casals M，Brahmer JR，Callahan MK，et al. Immune-related adverse events of checkpoint inhibitors [J]. Nat Rev Dis Primers，2020，6（1）：38.
[30] Bagchi S，Yuan R，Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer：Clinical Impact and Mechanisms of Response and Resistance [J]. Annu Rev Pathol，2021，16：223-249.